Is onct a good buy

**Oncternal Therapeutics (ONCT) is not a good buy at this time.** Here are the key reasons:

1. **Financial Performance**: ONCT has reported a net loss of $8.56 million and a diluted EPS of -$2.89 for the most recent quarter, indicating financial instability.
2. **Revenue Decline**: The company has experienced a significant decline in revenue, which could be a concern for investors.
3. **Negative Valuation Ratios**: The company's P/E(TTM) is negative at -0.12, and its P/S ratio is also negative at 3.93, which is a red flag for investors.
4. **Technical Indicators**: The technical indicators are not favorable. The stock is trading below its 5-day, 10-day, and 50-day moving averages, and the RSI, MACD, and KDJ values do not strongly suggest a buy.
5. **Market Sentiment**: There is a negative sentiment towards the stock, with a recent decline in share price and a lack of a consensus rating and price target from analysts, which could suggest a lack of confidence in the stock's future performance.

In conclusion, despite the potential for growth in the biotechnology sector, Oncternal Therapeutics' financial losses, revenue decline, and negative valuation ratios suggest that the stock may not be a good buy at this time. Investors should exercise caution and consider these factors before making an investment decision.